Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  11:31:24 2023-01-27 am EST
0.0293 CHF   -1.01%
01/17RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
CI
01/17Relief Therapeutics Wins Review Board's Nod for Planned Clinical Study of Skin Cancer Drug
MT
01/17Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

11/14/2022 | 01:05am EST

Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

14-Nov-2022 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

Geneva, Switzerland and Radnor, Pennsylvania, November 14, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx Pharmaceuticals"), today announced that they have entered into definitive settlement agreements to resolve their pending litigation.  As part of the settlement, at a closing to be held within the next 30 days, (i) NRx Pharmaceuticals will transfer to Relief all of the assets that it previously used in its aviptadil development program, including its regulatory filings, patent applications, clinical data, and the formulation of the aviptadil product it was previously developing, (ii) Relief will have the exclusive right and control going forward and the obligation to use commercially reasonable efforts to develop and commercialize an aviptadil product, (iii) Relief has agreed to use commercially reasonable efforts to continue the existing Right to Try Program for aviptadil in the United States for at least 2 years, (iv) Relief will pay NRx Pharmaceuticals milestone payments if it can successfully obtain commercial approval of an aviptadil product (whether for COVID-19 or any other indication), (v) Relief will pay NRx Pharmaceuticals royalties based on a percentage of future sales of an aviptadil product (whether for COVID-19 or any other indication), up to a maximum of $30 million in the aggregate, (vi) NRx Pharmaceuticals has agreed not to compete in the development of an aviptadil product in the future, and (vii) at the closing, Relief and NRx Pharmaceuticals will dismiss their pending litigation. There can be no assurance that Relief will be successful at commercializing the aviptadil product.

About Relief Therapeutics
Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of rare and ultra-rare diseases including metabolic disorders, pulmonary diseases, and connective tissue disorders. Relief’s diversified pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE®, engineered with the proprietary Physiomimic technology, which is the first prolonged-release amino acid product commercialized for the dietary management of phenylketonuria (“PKU”). Relief has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including Urea Cycle Disorders (“UCDs”) and Maple Syrup Urine Disease (“MSUD”). Relief also continues to develop aviptadil for several rare pulmonary indications. Further, Relief is in clinical development for APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa (“EB”), a group of rare, genetic, life-threatening connective tissue disorders; APR-TD011 has been granted Orphan Drug Designation by the FDA. Finally, Relief is commercializing several legacy products via licensing and distribution partners.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTD. For more information, visit www.relieftherapeutics.com. Follow Relief on LinkedIn.

About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain’s NMDA receptor and is being investigated in a Phase 3 trial under a Food and Drug Administration ("FDA") Special Protocol Agreement and Breakthrough Therapy Designation in patients with bipolar depression and acute suicidal ideation, an indication for which the only approved treatment is electroshock therapy. NRx Pharmaceuticals has also initiated a Phase 2b clinical trial in patients with Sub-Acute Suicidality, potentially a substantially broader indication. The Breakthrough Therapy Designation and Special Protocol Agreement were awarded by the FDA based on the Company’s prior STABIL-B trial that demonstrated substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether the parties can successfully close their settlement, and (ii) those factors described in Relief's and NRx Pharmaceuticals' reports to the Securities and Exchange Commission under the Securities Exchange Act of 1934 could adversely affect Relief and NRx, respectively. Copies of Relief's and NRx's filings with the SEC are available on the SEC EDGAR database at www.sec.gov. Relief and NRx do not undertake any obligation to update the information contained herein, which speaks only as of this date.
 

CONTACT:

RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com
NRX PHARMACEUTICALS, INC.
Molly Cogan
Sr. Director, Global Communications
mcogan@nrxpharma.com

FOR MEDIA/INVESTOR INQUIRIES:

LifeSci Advisors                                  
Irina Kofflerr
ikoffler@lifesciadvisors.com
+1-917-734-7387   
Stern Investor Relations
Suzanne Messer
suzanne.messere@sternir.com

Additional features:


File: Ad hoc

End of Inside Information
Language: English
Company: Relief Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: +41 22 545 11 16
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Valor: 10019113
Listed: SIX Swiss Exchange
EQS News ID: 1486229

 
End of Announcement EQS News Service

1486229  14-Nov-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1486229&application_name=news&site_id=zonebourse_sftp

ę EQS 2022
All news about RELIEF THERAPEUTICS HOLDING AG
01/17RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial E..
CI
01/17Relief Therapeutics Wins Review Board's Nod for Planned Clinical Study of Skin Cancer D..
MT
01/17Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating R..
EQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVAfor Pati..
AQ
2022Acer Therapeutics' Olpruva Approved by FDA, Triggers Availability of $42.5 Million Loan
MT
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ ..
AQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ f..
CI
2022Relief Therapeutics, Acer Therapeutics Win US FDA Nod For Urea Cycle Disorders Treatmen..
MT
2022Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 wit..
EQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ ..
EQ
More news
Financials
Sales 2022 12,0 M 13,0 M 13,0 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 129 M 140 M 140 M
Capi. / Sales 2022 10,7x
Capi. / Sales 2023 5,60x
Nbr of Employees 10
Free-Float 71,7%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,03 CHF
Average target price 0,32 CHF
Spread / Average Target 1 006%
Managers and Directors
Jack M. Weinstein Chief Executive Officer
Jeremy Meinen Chief Financial Officer
Raghuram Selvaraju Chairman
Nermeen Varawalla Chief Medical Officer
Paolo Galfetti Chief Operating Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-2.33%140
MODERNA, INC.7.58%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.55%28 465
SEAGEN INC.9.46%26 117